Darum lohnt es sich
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison.
Key aspects of this role will include engaging in peer‑to‑peer scientific dialogue with healthcare professionals that translate into meaningful insights, serving as a therapeutic expert and thought partner to internal teams, acting as a liaison between Revolution Medicines and clinical study sites/investigators, and providing support for medical education, advisory boards, and medical congresses.
Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Rev Revolution Medicines is a late‑stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers.
The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.
